このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Emergent BioSolutions 過去の業績
過去 基準チェック /06
Emergent BioSolutionsの収益は年間平均-59%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 1.8%割合で 増加しています。
主要情報
-59.0%
収益成長率
-59.6%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 1.8% |
| 株主資本利益率 | -85.1% |
| ネット・マージン | -47.7% |
| 前回の決算情報 | 31 Mar 2024 |
最近の業績更新
Recent updates
Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround
May 10New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Emergent BioSolutions: Making A Big Bet On Narcan
Jul 21An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued
Jun 22
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Emergent Biosolutions Q4 2022 Earnings Preview
Feb 24An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued
Feb 16Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M
Feb 15Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments
Dec 07Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance
Nov 09Emergent doses first participant in Phase 1 trial for Lassa virus vaccine
Sep 06Emergent BioSolutions: Now Long Through Sale Of October Put Spreads
Aug 24A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)
Aug 13Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant
Aug 12Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss
Aug 01Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
Jul 26Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Jul 26Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig
Jul 06Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak
May 29Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate
May 12収支内訳
収支内訳
Emergent BioSolutions の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 24 | 1,185 | -565 | 357 | -23 |
| 31 Dec 23 | 1,049 | -760 | 368 | 0 |
| 30 Sep 23 | 1,102 | -781 | 368 | 38 |
| 30 Jun 23 | 1,072 | -605 | 364 | 38 |
| 31 Mar 23 | 974 | -394 | 351 | 38 |
| 31 Dec 22 | 1,118 | -212 | 340 | 0 |
| 30 Sep 22 | 1,491 | 33 | 341 | 0 |
| 30 Jun 22 | 1,581 | 88 | 341 | 0 |
| 31 Mar 22 | 1,757 | 158 | 352 | 0 |
| 31 Dec 21 | 1,774 | 220 | 349 | 0 |
| 30 Sep 21 | 1,653 | 227 | 336 | 0 |
| 30 Jun 21 | 1,709 | 299 | 330 | 0 |
| 31 Mar 21 | 1,706 | 387 | 315 | 0 |
| 31 Dec 20 | 1,577 | 306 | 304 | 0 |
| 30 Sep 20 | 1,333 | 167 | 289 | 0 |
| 30 Jun 20 | 1,259 | 170 | 278 | 0 |
| 31 Mar 20 | 1,108 | 68 | 273 | 0 |
| 31 Dec 19 | 1,106 | 55 | 274 | 0 |
| 30 Sep 19 | 1,016 | 4 | 278 | 0 |
| 30 Jun 19 | 878 | -18 | 255 | 0 |
| 31 Mar 19 | 855 | 42 | 223 | 0 |
| 31 Dec 18 | 782 | 63 | 203 | 0 |
| 30 Sep 18 | 706 | 100 | 163 | 0 |
| 30 Jun 18 | 681 | 113 | 156 | 0 |
| 31 Mar 18 | 562 | 67 | 148 | 0 |
| 31 Dec 17 | 561 | 83 | 143 | 0 |
| 30 Sep 17 | 519 | 81 | 131 | 0 |
| 30 Jun 17 | 512 | 68 | 133 | 0 |
| 31 Mar 17 | 503 | 61 | 137 | 0 |
| 31 Dec 16 | 489 | 63 | 143 | 0 |
| 30 Sep 16 | 497 | 73 | 139 | 0 |
| 30 Jun 16 | 512 | 94 | 128 | 0 |
| 31 Mar 16 | 529 | 125 | 119 | 0 |
| 31 Dec 15 | 489 | 91 | 121 | 0 |
| 30 Sep 15 | 478 | 79 | 110 | 0 |
| 30 Jun 15 | 457 | 59 | 115 | 0 |
| 31 Mar 15 | 460 | 35 | 119 | 0 |
| 31 Dec 14 | 404 | 54 | 109 | 0 |
| 30 Sep 14 | 400 | 22 | 109 | 0 |
| 30 Jun 14 | 351 | 14 | 101 | 0 |
| 31 Mar 14 | 324 | 19 | 91 | 0 |
| 31 Dec 13 | 313 | 31 | 85 | 0 |
| 30 Sep 13 | 309 | 32 | 82 | 0 |
| 30 Jun 13 | 287 | 25 | 79 | 0 |
質の高い収益: EBSは現在利益が出ていません。
利益率の向上: EBSは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: EBSは利益が出ておらず、過去 5 年間で損失は年間59%の割合で増加しています。
成長の加速: EBSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: EBSは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。
株主資本利益率
高いROE: EBSは現在利益が出ていないため、自己資本利益率 ( -85.15% ) はマイナスです。